Pasar al contenido principal

OBESIDAD Y COMORBILIDADES: INVESTIGACION DEL INTERACTOMA TISULAR/CELULAR EN SU DESARROLLO Y APROXIMACIONES TERAPEUTICAS

PID2021-122766OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 23
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Mouse and human striatal projection neurons compared - somatodendritic arbor, spines and in silico analyses

  • Kozlov, Alexander
  • Blazquez Llorca, Lidia
  • Benavides Piccione, Ruth
  • Kastanauskaite, Asta
  • Rojo, Ana I.
  • Muñoz Céspedes, Alberto
  • Cuadrado, Antonio
  • DeFelipe, Javier
  • Grillner, Sten
Dysfunction of the basal ganglia is implicated in a wide range of neurological and psychiatric disorders. Our understanding of the operation of the basal ganglia is largely derived on data from studies conducted on mice, which are frequently used as model organisms for various clinical conditions. The striatum, the largest compartment of the basal ganglia, consists of 90-95% striatal projection neurons (SPNs). It is therefore crucial to establish if human and mouse SPNs have distinct or similar properties, as this has implications for the relevance of mouse models for understanding the human striatum. To address this, we compared the general organization of the somato-dendritic tree of SPNs, the dimensions of the dendrites, the density and size of spines (spine surface area), and ion channel subtypes in human and mouse SPNs. Our findings reveal that human SPNs are significantly larger, but otherwise the organisation of the dendritic tree (dendrogram) with an average of approximately 5 primary dendrites, is similar in both species. Additionally in both humans and mice, over 90% of the spines are located on the terminal branches of each dendrite. Human spines are somewhat larger (4.3 versus 3.1 μm2) and the terminal dendrites have a uniform diameter in both humans and mice, although somewhat broader in the latter (1.0 versus 0.6 μm). The composition of ion channels is also largely conserved. These data have been used to simulate human SPNs building on our previous detailed simulation of mouse SPNs. We conclude that the human SPNs essentially appear as enlarged versions of the mouse SPNs. This similarity suggests that both species process information in a comparable manner, supporting the relevance of mouse models for studying the human striatum.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Saturated fatty acid-enriched small extracellular vesicles mediate a crosstalk inducing liver inflammation and hepatocyte insulin resistance

  • García Martínez, Irma
  • Alén, Rosa
  • Pereira, Laura
  • Povo-Retana, Adrián
  • Astudillo, Alma M.
  • Hitos, Ana B.
  • Gomez-Hurtado, Isabel
  • López-Collazo, Eduardo
  • Boscá, Lisardo
  • Francés, Rubén
  • Lizasoain, Ignacio
  • Moro, María Ángeles
  • Balsinde, Jesús
  • Izquierdo, Manuel
  • Valverde, Ángela M.
[Background & Aims]: Lipotoxicity triggers non-alcoholic fatty liver disease (NAFLD) progression owing to the accumulation of toxic lipids in hepatocytes including saturated fatty acids (SFAs), which activate pro-inflammatory pathways. We investigated the impact of hepatocyte- or circulating-derived small extracellular vesicles (sEV) secreted under NAFLD conditions on liver inflammation and hepatocyte insulin signalling. [Methods]: sEV released by primary mouse hepatocytes, characterised and analysed by lipidomics, were added to mouse macrophages/Kupffer cells (KC) to monitor internalisation and inflammatory responses. Insulin signalling was analysed in hepatocytes exposed to conditioned media from sEV-loaded macrophages/KC. Mice were i.v. injected sEV to study liver inflammation and insulin signalling. Circulating sEV from mice and humans with NAFLD were used to evaluate macrophage–hepatocyte crosstalk. [Results]: Numbers of sEV released by hepatocytes increased under NAFLD conditions. Lipotoxic sEV were internalised by macrophages through the endosomal pathway and induced pro-inflammatory responses that were ameliorated by pharmacological inhibition or deletion of Toll-like receptor-4 (TLR4). Hepatocyte insulin signalling was impaired upon treatment with conditioned media from macrophages/KC loaded with lipotoxic sEV. Both hepatocyte-released lipotoxic sEV and the recipient macrophages/KC were enriched in palmitic (C16:0) and stearic (C18:0) SFAs, well-known TLR4 activators. Upon injection, lipotoxic sEV rapidly reached KC, triggering a pro-inflammatory response in the liver monitored by Jun N-terminal kinase (JNK) phosphorylation, NF-κB nuclear translocation, pro-inflammatory cytokine expression, and infiltration of immune cells into the liver parenchyma. sEV-mediated liver inflammation was attenuated by pharmacological inhibition or deletion of TLR4 in myeloid cells. Macrophage inflammation and subsequent hepatocyte insulin resistance were also induced by circulating sEV from mice and humans with NAFLD. [Conclusions]: We identified hepatocyte-derived sEV as SFA transporters targeting macrophages/KC and activating a TLR4-mediated pro-inflammatory response enough to induce hepatocyte insulin resistance., This work was supported by grants PID2021-122766OB-I00 (AMV), PID2019-105989RB-I00 (JB), PID2020-113238RB-I00 (LB), PID2019-106581RB-I00 (MAM), PID2020-114148RB-I00 (MI), PID2019-107036RB-I00 (RF), and RD21/0006/0001 (ISCIII) (IL) funded by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación/10.13039/501100011033 and ERDF ‘A way of making Europe’ by the European Union (MICINN/AEI/FEDER, EU), grant EFSD/Boehringer Ingelheim European Research Programme on ‘Multi-System Challenges in Diabetes’ from the European Foundation for the Study of Diabetes (AMV), P2022/BMD-7227 (Comunidad de Madrid, Spain) (AMV), Fundación Ramón Areces (Spain) (AMV), CIBERdem (AMV and JB), CIBERhed (RF), and CIBERcv (LB) (ISCIII, Spain). LB and AMV belong to the Spanish National Research Council’s (CSIC’s) Cancer Hub. We also acknowledge the Spanish Ministry of Economy and Competitiveness (MINECO) postdoctoral contract IJCI-2015-24758 to IGM and the Spanish Ministry of Education, Culture and Sport (MECD) FPU17/02786 grant to RA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Maresin 1 activates brown adipose tissue and promotes browning of white adipose tissue in mice

  • Laiglesia, Laura M.
  • Escoté, Xavier
  • Sáinz, Neira
  • Felix-Soriano, Elisa
  • Santamaría, Eva
  • Collantes, María
  • Fernández-Galilea, Marta
  • Colón-Mesa, Ignacio
  • Martínez-Fernández, Leyre
  • Quesada-López, Tania
  • Quesada-Vázquez, Sergio
  • Rodríguez-Ortigosa, Carlos
  • Arbones-Mainar, José M.
  • Valverde, Ángela M.
  • Martínez, J. Alfredo
  • Dalli, Jesmond
  • Herrero, Laura
  • Lorente-Cebrián, Silvia
  • Villarroya, Francesc
  • Moreno-Aliaga, María Jesús
[Objective]: Maresin 1 (MaR1) is a docosahexaenoic acid-derived proresolving lipid mediator with insulin-sensitizing and anti-steatosis properties. Here, we aim to unravel MaR1 actions on brown adipose tissue (BAT) activation and white adipose tissue (WAT) browning. [Methods]: MaR1 actions were tested in cultured murine brown adipocytes and in human mesenchymal stem cells (hMSC)-derived adipocytes. In vivo effects of MaR1 were tested in diet-induced obese (DIO) mice and lean WT and Il6 knockout (Il6−/−) mice. [Results]: In cultured differentiated murine brown adipocytes, MaR1 reduces the expression of inflammatory genes, while stimulates glucose uptake, fatty acid utilization and oxygen consumption rate, along with the upregulation of mitochondrial mass and genes involved in mitochondrial biogenesis and function and the thermogenic program. In Leucine Rich Repeat Containing G Protein-Coupled Receptor 6 (LGR6)-depleted brown adipocytes using siRNA, the stimulatory effect of MaR1 on thermogenic genes was abrogated. In DIO mice, MaR1 promotes BAT remodeling, characterized by higher expression of genes encoding for master regulators of mitochondrial biogenesis and function and iBAT thermogenic activation, together with increased M2 macrophage markers. In addition, MaR1-treated DIO mice exhibit a better response to cold-induced BAT activation. Moreover, MaR1 induces a beige adipocyte signature in inguinal WAT of DIO mice and in hMSC-derived adipocytes. MaR1 potentiates Il6 expression in brown adipocytes and BAT of cold exposed lean WT mice. Interestingly, the thermogenic properties of MaR1 were abrogated in Il6−/− mice. [Conclusions]: These data reveal MaR1 as a novel agent that promotes BAT activation and WAT browning by regulating thermogenic program in adipocytes and M2 polarization of macrophages. Moreover, our data suggest that LGR6 receptor is mediating MaR1 actions on brown adipocytes, and that IL-6 is required for the thermogenic effects of MaR1., The authors received support for the current study from Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, Spain, MCIN/AEI/10.13039/501100011033 (grants BFU2012-36089 to MJM-A; BFU2015-65937-R to MJM-A, SL-C; PID2019-106982RB-I00 to MJM-A; SAF2017-83813-C3-1-R to LH and PID2021-122766OB-I00 to AMV), cofinanced by the European Regional Development Fund (ERDF); Dept. of Health, Navarra Government (67–2015) to MJM-A; Merck Health Foundation to LH; CIBEROBN (CB12/03/30002; CB06/03/0001; CB06/03/0025) and CIBERDEM (CB07/08/0033) from ISCIII (Spain). “Juan de la Cierva” Grant to MF-G (IJCI-2016-30025) funded by MCIN/AEI/10.13039/501100011033. Predoctoral grant to LML (Asociación de Amigos, Universidad de Navarra/“la Caixa” Banking Foundation) and to LM-F (FPI, BES-2013-064970). S.Q.-V. is supported by a fellowship from the Vicente Lopez Program (Eurecat)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MiR-7 controls cholesterol biosynthesis through posttranscriptional regulation of DHCR24 expression

  • Fernández-de Frutos, Mario
  • Pardo-Marqués, Virginia
  • Torrecilla-Parra, Marta
  • Rada, Patricia
  • Pérez-García, Ana
  • Martín-Martín, Yolanda
  • Peña, Gema de la
  • Gómez Peris, Ana
  • Toledano-Zaragoza, Ana
  • Gómez-Coronado, Diego
  • Casarejos, María José
  • Solís, José M.
  • Rotllan, Noemí
  • Pastor, Óscar
  • Ledesma, M. Dolores
  • Valverde, Ángela M.
  • Busto, Rebeca
  • Ramírez, Cristina M.
Dysregulation of cholesterol homeostasis is associated with several pathologies including cardiovascular diseases and neurological disorders such as Alzheimer's disease (AD). MicroRNAs (miRNAs) have emerged as key post-transcriptional regulators of cholesterol metabolism. We previously established the role of miR-7 in regulating insulin resistance and amyloidosis, which represents a common pathological feature between type 2 diabetes and AD. We show here an additional metabolic function of miR-7 in cholesterol biosynthesis. We found that miR-7 blocks the last steps of the cholesterol biosynthetic pathway in vitro by targeting relevant genes including DHCR24 and SC5D posttranscriptionally. Intracranial infusion of miR-7 on an adeno-associated viral vector reduced the expression of DHCR24 in the brain of wild-type mice, supporting in vivo miR-7 targeting. We also found that cholesterol regulates endogenous levels of miR-7 in vitro, correlating with transcriptional regulation through SREBP2 binding to its promoter region. In parallel to SREBP2 inhibition, the levels of miR-7 and hnRNPK (the host gene of miR-7) were concomitantly reduced in brain in a mouse model of Niemann Pick type C1 disease and in murine fatty liver, which are both characterized by intracellular cholesterol accumulation. Taken together, the results establish a novel regulatory feedback loop by which miR-7 modulates cholesterol homeostasis at the posttranscriptional level, an effect that could be exploited for therapeutic interventions against prevalent human diseases., This work was supported by the “Talento Program” from the Madrid Government, Spain (2017-T1/BMD-5333 and 2021-5A/BMD-20964), (RTI2018-095061-B-I00) and (PID2021-128264OB-I00) funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union (to CMR); Consejería de Educación e Investigación from the Madrid Government, Spain: “Convocatoria de ayudas para la contratación de ayudantes de investigación” (PEJ-2018-AI/BMD-9724) (to CMR and MT-P); “Convocatoria de ayudas para la contratación de investigadores postdoctorales” (PEDJ-2018-POST/BDM-8900) (to CMR and AP-G) and “Convocatoria de ayudas para la contratación de investigadores predoctorales” (PEJD-2019-PRE/BMD-14499) (to CMR and YM-M) from the Madrid Government, Spain; (RTI2018-098113-B-I00) (to RB and DGC) and (PID2021-122766OB-I00) (to AMV) and (PID2020-112830RB-I00) (to MD-L) funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union; (PI18/01152 and PI21/01173) funded by Instituto de Salud Carlos III, (ISCIII) (to OP); Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem), Instituto de Salud Carlos III, Madrid, Spain (research contract of P-R) and 2021-5A/BMD-20964 (research contract of VP-M). We thank the Quantification and Molecular Characterization Unit and the Lipid and Lipoprotein Unit (IRYCIS) for support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ

  • Zhang, Meijian
  • Barroso, Emma
  • Ruart, Maria
  • Peña, Lucía
  • Peyman, Mona
  • Aguilar-Recarte, David
  • Montori-Grau, Marta
  • Rada, Patricia
  • Cugat, Clara
  • Montironi, Carla
  • Zarei, Mohammad
  • Jurado-Aguilar, Javier
  • Camins, Antoni
  • Balsinde, Jesús
  • Valverde, Ángela M.
  • Wahli, Walter
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR)α and β/δ agonist that has reached a phase III clinical trial for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we examined the effects of elafibranor in mice fed a choline-deficient high-fat diet (CD-HFD), a model of metabolic dysfunction-associated steatohepatitis (MASH) that presents obesity and insulin resistance. Our findings revealed that elafibranor treatment ameliorated steatosis, inflammation, and fibrogenesis in the livers of CD-HFD-fed mice. Unexpectedly, elafibranor also increased the levels of the epithelial-mesenchymal transition (EMT)-promoting protein S100A4 via PPARβ/δ activation. The increase in S100A4 protein levels caused by elafibranor was accompanied by changes in the levels of markers associated with the EMT program. The S100A4 induction caused by elafibranor was confirmed in the BRL-3A rat liver cells and a mouse primary hepatocyte culture. Furthermore, elafibranor reduced the levels of ASB2, a protein that promotes S100A4 degradation, while ASB2 overexpression prevented the stimulating effect of elafibranor on S100A4. Collectively, these findings reveal an unexpected hepatic effect of elafibranor on increasing S100A4 and promoting the EMT program., This study was partly supported by the grants RTI2018-093999-B-I00 and PID2021-122116OB-I00 (M.V-C.), PID2021-122766OB-I00 (A.M.V.), and PID2019-105989RB-I00 (J.B.) from MCIN/AEI/10.13039/501100011033 and “ERDF, A Way of Making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. Support was also received from the CERCA Programme/Generalitat de Catalunya. Meijian Zhang was supported by a grant from the China Scholarship Council (CSC) (202007565030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD

  • Marsal-Beltran, Anna
  • Rodríguez-Castellano, Adrià
  • Astiarraga, Brenno
  • Calvo, Enrique
  • Rada, Patricia
  • Madeira, Ana
  • Rodríguez-Peña, M-Mar
  • Llauradó, Gemma
  • Núñez-Roa, Catalina
  • Gómez-Santos, Beatriz
  • Maymó-Masip, Elsa
  • Bosch, Ramón
  • Frutos, María Dolores
  • Moreno-Navarrete, José María
  • Ramos-Molina, Bruno
  • Aspichueta, Patricia
  • Joven, Jorge
  • Fernández-Real, José M.
  • Quer, Juan Carlos
  • Valverde, Ángela M.
  • Pardo, Albert
  • Vendrell, Joan
  • Ceperuelo-Mallafré, Victoria
  • Fernández-Veledo, Sonia
[Objective]: Succinate and succinate receptor 1 (SUCNR1) are linked to fibrotic remodeling in models of non-alcoholic fatty liver disease (NAFLD), but whether they have roles beyond the activation of hepatic stellate cells remains unexplored. We investigated the succinate/SUCNR1 axis in the context of NAFLD specifically in hepatocytes., [Methods]: We studied the phenotype of wild-type and Sucnr1−/− mice fed a choline-deficient high-fat diet to induce non-alcoholic steatohepatitis (NASH), and explored the function of SUCNR1 in murine primary hepatocytes and human HepG2 cells treated with palmitic acid. Lastly, plasma succinate and hepatic SUCNR1 expression were analyzed in four independent cohorts of patients in different NAFLD stages., [Results]. Sucnr1 was upregulated in murine liver and primary hepatocytes in response to diet-induced NASH. Sucnr1 deficiency provoked both beneficial (reduced fibrosis and endoplasmic reticulum stress) and detrimental (exacerbated steatosis and inflammation and reduced glycogen content) effects in the liver, and disrupted glucose homeostasis. Studies in vitro revealed that hepatocyte injury increased Sucnr1 expression, which when activated improved lipid and glycogen homeostasis in damaged hepatocytes. In humans, SUCNR1 expression was a good determinant of NAFLD progression to advanced stages. In a population at risk of NAFLD, circulating succinate was elevated in patients with a fatty liver index (FLI) ≥60. Indeed, succinate had good predictive value for steatosis diagnosed by FLI, and improved the prediction of moderate/severe steatosis through biopsy when added to an FLI algorithm., [Conclusions]. We identify hepatocytes as target cells of extracellular succinate during NAFLD progression and uncover a hitherto unknown function for SUCNR1 as a regulator of hepatocyte glucose and lipid metabolism. Our clinical data highlight the potential of succinate and hepatic SUCNR1 expression as markers to diagnose fatty liver and NASH, respectively., This study was supported by grants from MCIN/AEI/10.13039/501100011033 (SAF2015-65019-R, RTI2018-093919-B-100 and PID2021-122480OB-100 to S.F.-V.; PID2021-122766OB-100 to A.M.V; PID2021-124425OB-I00 to P.A.) co-financed by the European Regional Development Fund (ERDF) and Grupos consolidados Gobierno Vasco IT1476-22 to P.A. This research was funded by the Institute of Health “Carlos III” (ISCIII) and co-financed by ERDF (PI20/00095 to V.C.-M.; PI20/00338 to J.V. and PI20/00505 to B.R.-M.). This study was also supported by a grant from ISCIII and CIBERDEM, DEM19PI01/2019 to V.C.-M. and P.R. The project that gave rise to these results received funding from “La Caixa” Foundation (ID 100010434), under the grant agreement LCF/PR/HR20/52400013 (to S.F.-V.). This study was also supported by Rovira i Virgili University and Tarragona Provincial Council with the Talent Salut fellowship to A.R.-C. A.M.-B. is a recipient of an FPU grant (FPU20/05633) from MCIN/AEI/10.13039/501100011033. B.A. acknowledges support from the PERIS program 2016–2020 (LT017/20/000033), from Departament de Salut de la Generalitat de Catalunya. V.C.-M. acknowledges support from the Ramón y Cajal program (RYC2019-02649-I), from MCIN/AEI/10.13039/501100011033/ and the European Social Fund (ESF), “Investing in your future”. B.R.-M. acknowledges support from the Miguel Servet Type I program (CP19/00098) from the Fondo de Investigación Sanitaria, co-financed by the ERDF. SFV and JVO acknowledge support from the Agency for Management of University Research Grants of the Generalitat de Catalunya (2021 SGR 01409, 2021 SGR 0089). The study was also supported by CIBER–Consorcio Centro de Investigación Biomédica en Red (CB07708/0012), ISCIII, Ministerio de Ciencia e Innovación., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble epoxide hydrolase-targeting PROTAC activates AMPK and inhibits endoplasmic reticulum stress

  • Peyman, Mona
  • Barroso, Emma
  • Turcu, Andreea L.
  • Estrany Jr., Francesc
  • Smith, Dáire
  • Jurado-Aguilar, Javier
  • Rada, Patricia
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Valverde, Ángela M.
  • Palomer, Xavier
  • Galdeano, Carles
  • Vázquez, Santiago
  • Vázquez-Carrera, Manuel
Soluble epoxide hydrolase (sEH) is a drug target with the potential for therapeutic utility in the areas of inflammation, neurodegenerative disease, chronic pain, and diabetes, among others. Proteolysis-targeting chimeras (PROTACs) molecules offer new opportunities for targeting sEH, due to its capacity to induce its degradation. Here, we describe that the new ALT-PG2, a PROTAC that degrades sEH protein in the human hepatic Huh-7 cell line, in isolated mouse primary hepatocytes, and in the liver of mice. Remarkably, sEH degradation caused by ALT-PG2 was accompanied by an increase in the phosphorylated levels of AMP-activated protein kinase (AMPK), while phosphorylated extracellular-signal-regulated kinase 1/2 (ERK1/2) was reduced. Consistent with the key role of these kinases on endoplasmic reticulum (ER) stress, ALT-PG2 attenuated the levels of ER stress and inflammatory markers. Overall, the findings of this study indicate that targeting sEH with degraders is a promising pharmacological strategy to promote AMPK activation and to reduce ER stress and inflammation., This study was partly supported by grants RTI2018-093999-B-100 and PID2021-122116OB-I00 (M.V-C.), PID2020-118127RB-I00 (S.V.), PID2021-127693OB-I00 (C.G.) and PID2021-122766OB-I00 (A.M.V.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. CERCA Programme/Generalitat de Catalunya. Partial support was provided by NIH – NIEHS (RIVER Award) R35 ES030443-01, NIH – NIEHS (Superfund Award) P42 ES004699 and NIH Counter Act Award U54 NS127758 (B.H.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury

  • Marañón, Patricia
  • Rey, Esther
  • Isaza, Stephania C.
  • Wu, Hanghang
  • Rada, Patricia
  • Choya-Foces, Carmen
  • Martínez-Ruiz, Antonio
  • Martín, M. Ángeles
  • Ramos, Sonia
  • García-Monzón, Carmelo
  • Cubero, Francisco Javier
  • Valverde, Ángela M.
  • González-Rodríguez, Águeda
Acetaminophen (APAP)-induced liver injury is one of the most prevalent causes of acute liver failure (ALF). We assessed the role of the bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3 in APAP-induced hepatotoxicity. The molecular mechanisms that regulate the balance between cell death and survival and the response to oxidative stress induced by APAP was assessed in cultured human hepatocyte-derived (Huh7) cells treated with pharmacological inhibitors of ALK receptors and with modulated expression of ALK2 or ALK3 by lentiviral infection, and in a mouse model of APAP-induced hepatotoxicity. Inhibition of ALK3 signalling with the pharmacological inhibitor DMH2, or by silencing of ALK3, showed a decreased cell death both by necrosis and apoptosis after APAP treatment. Also, upon APAP challenge, ROS generation was ameliorated and, thus, ROS-mediated JNK and P38 MAPK phosphorylation was reduced in ALK3-inhibited cells compared to control cells. These results were also observed in an experimental model of APAP-induced ALF in which post-treatment with DMH2 after APAP administration significantly reduced liver tissue damage, apoptosis and oxidative stress. This study shows the protective effect of ALK3 receptor inhibition against APAP-induced hepatotoxicity. Furthermore, findings obtained from the animal model suggest that BMP signalling might be a new pharmacological target for the treatment of ALF., This study was supported by grants RTI2018-094203-B-I00 (to AMR), PID2020-11794RB-IOO (to FJC), PID2021-124688OB-I00 (to AMR) and PID2021-122766OB-100 (to AMV) and funded by MCIN/AEI/10.13039/501100011033 (Spain) and “ERDF A way of making Europe” by the European Union; the European Horizon's research and innovation programme HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679, funded by the European Union, and COST Action CA17112, supported by COST (European Cooperation in Science and Technology), to FJC, and contract CP19/00032, and grants PI16/00853 and PI19/00123 from Instituto de Salud Carlos III (ISCIII, Spain), partially funded by FEDER, and CIBERDEM (ISCIII, Spain) to AGR. FJC belongs to the validated Research Groups Ref. 970935 "Liver Pathophysiologÿ, 920631 "Lymphocyte immunobiologÿ, 920361 “Inmunogenética e inmunología de las mucosas” and IBL-6 (imas12-associated). CCF is supported by grant FPU18/03475 from the Ministerio de Universidades (Spain), partially funded by FEDER. PMB is supported by a research contracts (PEJD-2018-PRE/BMD-9500PEJ-2020-AI/BMD-19491) funded by Comunidad de Madrid (Spain). SCI is supported by a predoctoral contract (FI20-00296) from ISCIII/FEDER (Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway

  • Jurado-Aguilar, Javier
  • Barroso, Emma
  • Bernard, Maribel
  • Zhang, Meijian
  • Peyman, Mona
  • Rada, Patricia
  • Valverde, Ángela M.
  • Wahli, Walter
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
[Introduction]: The levels of the cellular energy sensor AMP-activated protein kinase (AMPK) have been reported to be decreased via unknown mechanisms in the liver of mice deficient in growth differentiation factor 15 (GDF15). This stress response cytokine regulates energy metabolism mainly by reducing food intake through its hindbrain receptor GFRAL., [Objective]: To examine how GDF15 regulates AMPK., [Methods]: Wild-type and Gdf15−/− mice, mouse primary hepatocytes and the human hepatic cell line Huh-7 were used., [Results]: Gdf15−/− mice showed glucose intolerance, reduced hepatic phosphorylated AMPK levels, increased levels of phosphorylated mothers against decapentaplegic homolog 3 (SMAD3; a mediator of the fibrotic response), elevated serum levels of transforming growth factor (TGF)-β1, as well as upregulated gluconeogenesis and fibrosis. In line with these observations, recombinant (r)GDF15 promoted AMPK activation and reduced the levels of phosphorylated SMAD3 and the markers of gluconeogenesis and fibrosis in the liver of mice and in mouse primary hepatocytes, suggesting that these effects may be independent of GFRAL. Pharmacological inhibition of SMAD3 phosphorylation in Gdf15−/− mice prevented glucose intolerance, the deactivation of AMPK and the increase in the levels of proteins involved in gluconeogenesis and fibrosis, suggesting that overactivation of the TGF-β1/SMAD3 pathway is responsible for the metabolic alterations in Gdf15−/− mice., [Conclusions]: Overall, these findings indicate that GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis by lowering the activity of the TGF-β1/SMAD3 pathway., This study was partly supported by the grants PID2021-122116OB-I00 (M.V.-C.) and PID2021-122766OB-I00 (A.M.V.) from MCIN/AEI/10.13039/501100011033 and “ERDF, A Way of Making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. Support was also received from the CERCA Programme/Generalitat de Catalunya. Meijian Zhang was supported by a grant from the China Scholarship Council (CSC) (202007565030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Uncovering a Novel Functional Interaction Between Adult Hepatic Progenitor Cells, Inflammation and EGFR Signaling During Bile Acids-Induced Injury

  • García-Sáez, Juan
  • Figueroa-Fuentes, María
  • González-Corralejo, Carlos
  • Roncero, Cesáreo
  • Lazcanoiturburu, Nerea
  • Gutiérrez-Uzquiza, Álvaro
  • Vaquero, Javier
  • González-Sánchez, Ester
  • Bhutia, Kunzangla
  • Calero-Pérez, Silvia
  • Maina, Flavio
  • Traba, Javier
  • Valverde, Ángela M.
  • Fabregat, Isabel
  • Herrera, Blanca
  • Sánchez, Aránzazu
Chronic cholestatic damage is associated to both accumulation of cytotoxic levels of bile acids and expansion of adult hepatic progenitor cells (HPC) as part of the ductular reaction contributing to the regenerative response. Here, we report a bile acid-specific cytotoxic response in mouse HPC, which is partially impaired by EGF signaling. Additionally, we show that EGF synergizes with bile acids to trigger inflammatory signaling and NLRP3 inflammasome activation in HPC. Aiming at understanding the impact of this HPC specific response on the liver microenvironment we run a proteomic analysis of HPC secretome. Data show an enrichment in immune and TGF-β regulators, ECM components and remodeling proteins in HPC secretome. Consistently, HPC-derived conditioned medium promotes hepatic stellate cell (HSC) activation and macrophage M1-like polarization. Strikingly, EGF and bile acids co-treatment leads to profound changes in the secretome composition, illustrated by an abolishment of HSC activating effect and by promoting macrophage M2-like polarization. Collectively, we provide new specific mechanisms behind HPC regulatory action during cholestatic liver injury, with an active role in cellular interactome and inflammatory response regulation. Moreover, findings prove a key contribution for EGFR signaling jointly with bile acids in HPC-mediated actions., This work was supported by Ministry of Science and Innovation, Spanish Agency of Research cofounded by FEDER (grants RTI2018-099098-B-100 to AS/BH; and grants PID2021-124830OB-100 and PID2021-122766OB-100 funded by MCIN/AEI/10.13039/501100011033 / FEDER, UE, to AS/BH and AMV, respectively) and by Fundación Ramon Areces, grant #CIVP20A6593, to IF. NL was supported by RTI2018-099098-B-100. JGS and MF were supported by UCM Santander predoctoral contract and Investigo Program Grant, respectively.The CIBEREHD is funded by the Instituto de Salud Carlos III, Spain. We thank CERCA programme/Generalitat de Catalunya for institutional support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Estrogens prevent the hypothalamus-periphery crosstalk induced by olanzapine intraperitoneal treatment in female mice: Effects on brown/beige adipose tissues and liver

  • Ferreira, Vítor
  • Folgueira, Cintia
  • Montes-San Lorenzo, Ángela
  • Rodríguez-López, Andrea
  • Gonzalez-Iglesias, Eva
  • Zubiaur, Pablo
  • Abad-Santos, Francisco
  • Sabio, Guadalupe
  • Rada, Patricia
  • Valverde, Ángela M.
Olanzapine (OLA) is a highly obesogenic second-generation antipsychotic (SGA). Recently we demonstrated that, contrarily to OLA oral treatment, intraperitoneal (i.p.) administration resulted in weight loss and absence of hepatic steatosis in wild-type (WT) and protein tyrosine phosphatase 1B (PTP1B)-deficient (KO) male mice. This protection relied on two central-peripheral axes connecting hypothalamic AMPK with brown/inguinal white adipose tissue (BAT/iWAT) uncoupling protein-1 (UCP-1) and hypothalamic JNK with hepatic fatty acid synthase (FAS). Herein, we addressed OLA i.p. treatment effects in WT and PTP1B-KO female mice. Contrarily to our previous results in WT females receiving OLA orally, the i.p. treatment did not induce weight gain or hyperphagia. Molecularly, in females OLA failed to diminish hypothalamic phospho-AMPK or elevate BAT UCP-1 and energy expenditure (EE) despite the preservation of iWAT browning. Conversely, OLA i.p. treatment in ovariectomized mice reduced hypothalamic phospho-AMPK, increased BAT/iWAT UCP-1 and EE, and induced weight loss as occurred in males. Pretreatment of hypothalamic neurons with 17β-estradiol (E2) abolished OLA effects on AMPK. Moreover, neither hypothalamic JNK activation nor hepatic FAS upregulation were found in WT and PTP1B-KO females receiving OLA via i.p. Importantly, this axis was reestablished upon ovariectomy. In this line, E2 prevented OLA-induced phospho-JNK in hypothalamic neurons. These results support the role of estrogens in sex-related dimorphism in OLA treatment. This study evidenced the benefit of OLA i.p. administration in preventing its obesogenic effects in female mice that could offer clinical value., This work was funded by grants PID2021-122766OB-I00 (to AMV) and PID2019-104399RB-I00 (to GS) funded by MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union (Spain). We also acknowledge grants H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236, European Commission) (to AMV and FA-S), and P2022/BMD-7227 (Comunidad de Madrid, Spain), and CIBERdem (ISCIII, Spain) (to AMV). VF was a recipient of a contract from ITN-TREATMENT and a PhD fellowship from the Portuguese Foundation for Science and Technology (2020.08388.BD, FCT, Portugal)/ERDF. CF was awarded with Sara Borrell contract (CD19/00078, ISCIII, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protein kinase D2 modulates hepatic insulin sensitivity in male mice

  • Rada, Patricia
  • Carceller-López, Elena
  • Hitos, Ana B.
  • Gómez-Santos, Beatriz
  • Fernández-Hernández, Constanza
  • Rey, Esther
  • Pose-Utrilla, Julia
  • García-Monzón, Carmelo
  • González-Rodríguez, Águeda
  • Sabio, Guadalupe
  • García, Antonia
  • Aspichueta, Patricia
  • Iglesias, Teresa
  • Valverde, Ángela M.
[Objectives]: Protein kinase D (PKD) family is emerging as relevant regulator of metabolic homeostasis. However, the precise role of PKD2 in modulating hepatic insulin signaling has not been fully elucidated and it is the aim of this study., [Methods]: PKD inhibition was analyzed for insulin signaling in mouse and human hepatocytes. PKD2 was overexpressed in Huh7 hepatocytes and mouse liver, and insulin responses were evaluated. Mice with hepatocyte-specific PKD2 depletion (PKD2ΔHep) and PKD2fl/fl mice were fed a chow (CHD) or high fat diet (HFD) and glucose homeostasis and lipid metabolism were investigated., [Results]: PKD2 silencing enhanced insulin signaling in hepatocytes, an effect also found in primary hepatocytes from PKD2ΔHep mice. Conversely, a constitutively active PKD2 mutant reduced insulin-stimulated AKT phosphorylation. A more in-depth analysis revealed reduced IRS1 serine phosphorylation under basal conditions and increased IRS1 tyrosine phosphorylation in PKD2ΔHep primary hepatocytes upon insulin stimulation and, importantly PKD co-immunoprecipitates with IRS1. In vivo constitutively active PKD2 overexpression resulted in a moderate impairment of glucose homeostasis and reduced insulin signaling in the liver. On the contrary, HFD-fed PKD2ΔHep male mice displayed improved glucose and pyruvate tolerance, as well as higher peripheral insulin tolerance and enhanced hepatic insulin signaling compared to control PKD2fl/fl mice. Despite of a remodeling of hepatic lipid metabolism in HFD-fed PKD2ΔHep mice, similar steatosis grade was found in both genotypes., [Conclusions]: Results herein have unveiled an unknown role of PKD2 in the control of insulin signaling in the liver at the level of IRS1 and point PKD2 as a therapeutic target for hepatic insulin resistance., This work was funded by grants PID2023-150994OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to PR; PID-2021-122766OB-100 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to AMV; PID2020-115218RB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to TI; PID2021-124425OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to PA; PDC2021-121147-I00 funded by MICIU/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR” to GS. We also acknowledge grants PI20/00837 to CG-M, PMP21/00057 to GS and PA, and PI22/01968 to ÁG-R funded by Instituto de Salud Carlos III/FEDER (Spain), and IT1476-22 funded by Basque Government, Department of Education (Spain) to PA, grants P2022/BMD-7227 funded by Comunidad de Madrid (Spain) to AMV and AG and funding from CIBERDEM (ISCIII, Spain) to AMV and CIBERNED (ISCIII, Spain) to TI, including PR and JPU research contracts, respectively. CNIC is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). EC-L is funded by Comunidad de Madrid and Fondo Social Europeo (ref. PEJ-2020-AI/BMD-18301)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH

  • Fernández-Ginés, Raquel
  • Encinar, José Antonio
  • Escoll, Maribel
  • Carnicero-Senabre, Daniel
  • Jiménez-Villegas, José
  • García-Yagüe, Ángel Juan
  • González-Rodríguez, Águeda
  • García-Martínez, Irma
  • Valverde, Ángela M.
  • Rojo, Ana I.
  • Cuadrado, Antonio
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease that compromises liver function, for which there is not a specifically approved medicine. Recent research has identified transcription factor NRF2 as a potential therapeutic target. However, current NRF2 activators, designed to inhibit its repressor KEAP1, exhibit unwanted side effects. Alternatively, we previously introduced PHAR, a protein-protein interaction inhibitor of NRF2/β-TrCP, which induces a mild NRF2 activation and selectively activates NRF2 in the liver, close to normal physiological levels. Herein, we assessed the effect of PHAR in protection against NASH and its progression to fibrosis. We conducted experiments to demonstrate that PHAR effectively activated NRF2 in hepatocytes, Kupffer cells, and stellate cells. Then, we used the STAM mouse model of NASH, based on partial damage of endocrine pancreas and insulin secretion impairment, followed by a high fat diet. Non-invasive analysis using MRI revealed that PHAR protects against liver fat accumulation. Moreover, PHAR attenuated key markers of NASH progression, including liver steatosis, hepatocellular ballooning, inflammation, and fibrosis. Notably, transcriptomic data indicate that PHAR led to upregulation of 3 anti-fibrotic genes (Plg, Serpina1a, and Bmp7) and downregulation of 6 pro-fibrotic (including Acta2 and Col3a1), 11 extracellular matrix remodeling, and 8 inflammatory genes. Overall, our study suggests that the mild activation of NRF2 via the protein-protein interaction inhibitor PHAR holds promise as a strategy for addressing NASH and its progression to liver fibrosis., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID-2021-122766OB-100 and PDC2021-121421-I00, PDC2022-133765-I00, MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” by the European Union.), CIBERdem and CIBERned (ISCIII), and The Autonomous Community of Madrid (grant P2022/BMD-7230). RFG enjoyed a FPI contract of MINECO (FPI-2017). DCS is a holder of a FPI contract of MICINN (Ministry of Science and Innovation, FPI-2020, PRE2020-091886). JJV is holder of a FPU contract of MIU (Ministry of Universities, FPU2020, FPU20/03326)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

  • Valdecantos, M. P.
  • Ruiz, Laura
  • Folgueira, Cintia
  • Rada, Patricia
  • Gómez-Santos, Beatriz
  • Solas, Maite
  • Hitos, Ana B.
  • Field, Joss
  • Francisco, Vera
  • Escalona-Garrido, Carmen
  • Zagmutt, Sebastián
  • Calderón‐Domínguez, María
  • Mera, Paula
  • García Martínez, Irma
  • Maymó-Masip, Elsa
  • Grajales, Diana
  • Alén, Rosa
  • Mora, Alfonso
  • Sáinz, Neira
  • Vides-Urrestarazu, Irene
  • Vilarrasa, Núria
  • Arbones-Mainar, José M
  • Zaragoza, Carlos
  • Moreno-Aliaga, María J.
  • Aspichueta, Patricia
  • Fernández-Veledo, Sonia
  • Vendrell, Joan
  • Serra, Dolors
  • Herrero, Laura
  • Schreiber, Renate
  • Zechner, Rudolf
  • Sabio, Guadalupe
  • Hornigold, David
  • Rondinone, Cristina M.
  • Jermutus, Lutz
  • Grimsby, J.
  • Valverde, Ángela M.
Bariatric surgery is effective for the treatment and remission of obesity and type 2 diabetes, but pharmacological approaches which exert similar metabolic adaptations are needed to avoid post-surgical complications. Here we show how G49, an oxyntomodulin (OXM) analog and dual glucagon/glucagon-like peptide-1 receptor (GCGR/GLP-1R) agonist, triggers an inter-organ crosstalk between adipose tissue, pancreas, and liver which is initiated by a rapid release of free fatty acids (FFAs) by white adipose tissue (WAT) in a GCGR-dependent manner. This interactome leads to elevations in adiponectin and fibroblast growth factor 21 (FGF21), causing WAT beiging, brown adipose tissue (BAT) activation, increased energy expenditure (EE) and weight loss. Elevation of OXM, under basal and postprandial conditions, and similar metabolic adaptations after G49 treatment were found in plasma from patients with obesity early after metabolic bariatric surgery. These results identify G49 as a potential pharmacological alternative sharing with bariatric surgery hormonal and metabolic pathways., This work was funded by grants RTI2018-094052-B-100 funded by MICIU/AEI/10.13039/501100011033/ and by ERDF “A way of making Europe” and PID-2021-122766OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU, P2022/BMD-7227 (Comunidad de Madrid, Spain) and CIBERDdem (ISCIII) to A.M.V. and M.P.V., grants PID2020-114953RB-C21 funded by MICIU/AEI/10.13039/501100011033 to L.H. and D.S., CB06/03/0001 (CIBERobn, ISCIII, Spain) and 2021SGR00367 (Government of Catalonia) to L.H., grants PID2019-106982RB-I00 funded by MICIU/AEI/10.13039/501100011033 and CB12/03/30002 (CIBERobn, ISCIII, Spain) to M.J.M.-A., grants AECC PROYE19047SABI, PMP21/00057 Infraestructura de Medicina de Precisión asociada a la Ciencia y Tecnología IMPACT-2021, Instituto de Salud Carlos III, PDC2021-121147-I00 funded by MICIU/AEI/10.13039/501100011033 and the “European Union NextGeneration/PRTR” and PID2022-138525OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF/EU to G.S., grant PID2021-122480OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU, and 2021 SGR 01409 (Generalitat de Catalunya) to S.F.V., grant PID2021-128737NB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU to M.S., grants PI20/00338, PI23/01133 (ISCIII, Spain), and 2021 SGR 00829 (Government of Catalunya) to J.V., grants PI17/01556 and PI22/01773 (ISCIII, Spain) to N.V., grants IT1476-22 funded by Basque Government, Department of Education and PID2021-124425OB-100 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU to P.A. and F7302 SFB‐Lipid‐Hydrolysis from the Austrian Science Fund FWF and 12CVD04 from the Leducq Foundation both to R.Z. C.F. was funded by EASO/Novo Nordisk New Investigator Award in Basic Sciences 2023, EFSD/Novo Nordisk Rising Star 2024 and IBSA Foundation Fellowship Endocrinology 2023. V.F. was supported by “Albert Renold Travel Fellowship” grant from EFSD., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The hepatocyte epidermal growth factor receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche

  • Gonzalez-Sanchez, Ester
  • Vaquero, Javier
  • Caballero-Díaz, Daniel
  • Grzelak, Jan
  • Fusté, Noel P.
  • Bertran, Esther
  • Amengual, Josep
  • Garcia-Saez, Juan
  • Martín-Mur, Beatriz
  • Gut, Marta
  • Esteve-Codina, Anna
  • Alay, Ania
  • Coulouarn, Cédric
  • Calero-Pérez, Silvia
  • Valdecantos, Pilar
  • Valverde, Ángela M.
  • Sánchez, Aranzazu
  • Herrera, Blanca
  • Fabregat, Isabel
Liver fibrosis is the consequence of chronic liver injury in the presence of an inflammatory component. Although the main executors of this activation are known, the mechanisms that lead to the inflammatory process that mediates the production of pro-fibrotic factors are not well characterized. Epidermal growth factor receptor (EGFR) signaling in hepatocytes is essential for the regenerative processes of the liver; however, its potential role in regulating the fibrotic niche is not yet clear. Our group generated a mouse model that expresses an inactive truncated form of the EGFR specifically in hepatocytes (ΔEGFR mice). Here, we have analyzed the response of WT and ΔEGFR mice to chronic treatment with carbon tetrachloride (CCl4), which induces a pro-inflammatory and fibrotic process in the liver. The results indicated that the hallmarks of liver fibrosis were attenuated in CCl4-treated ΔEGFR mice when compared with CCl4-treated WT mice, coinciding with a faster resolution of the fibrotic process and ameliorated damage. The absence of EGFR activity in hepatocytes induced changes in the pattern of immune cells in the liver, with a notable increase in the population of M2 macrophages, more related to fibrosis resolution, as well as in the population of lymphocytes related to eradication of the damage. Transcriptome analysis of hepatocytes, and secretome studies of extracellular media from in vitro experiments, allowed us to elucidate the specific molecular mechanisms regulated by EGFR that mediate hepatocyte production of both pro-fibrotic and pro-inflammatory mediators; these have consequences for the deposition of extracellular matrix proteins, as well as for the immune microenvironment. Overall, our study uncovered novel mechanistic insights regarding EGFR kinase-dependent actions in hepatocytes that reveal its key role in chronic liver damage., This work was supported by (i) Fundacion Ramon Areces 20th National Competition for Scientific and Technical Research in Life and Matter Science 2020, grant # CIVP20A6593, to IF; (ii) Ministerio de Ciencia e Innovación (MICINN), Spain, which is part of the Agencia Estatal de Investigación (AEI), through (a) the Retos Investigación grants, numbers: RTI2018-094079-B-100 (co-funded by European Regional Development Fund, ERDF, a way to build Europe) to IF; PID2021-122551OB-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to IF; RTI2018-099098-B-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to AS/BH; PID-2021-122766OB-100 funded by MCIN/AEI/10.13039/501100011033 to AMV; and (b) the Retos Colaboración grant number RTC2019-007125-1 to IF. JV was funded by MICINN/AEI, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and ‘Ramon y Cajal’ program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank CERCA Programme/Generalitat de Catalunya for institutional support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells

  • Zhang, Meijian
  • Barroso, Emma
  • Peña, Lucía
  • Rada, Patricia
  • Valverde, Ángela M.
  • Wahli, Walter
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
The role of peroxisome proliferator-activated receptor (PPAR)β/δ in hepatic fibrosis remains a subject of debate. Here, we examined the effects of a PPARβ/δ agonist on the pathogenesis of liver fibrosis and the activation of hepatic stellate cells (HSCs), the main effector cells in liver fibrosis, in response to the pro-fibrotic stimulus transforming growth factor-β (TGF-β). The PPARβ/δ agonist GW501516 completely prevented glucose intolerance and peripheral insulin resistance, blocked the accumulation of collagen in the liver, and attenuated the expression of inflammatory and fibrogenic genes in mice fed a choline-deficient high-fat diet (CD-HFD). The antifibrogenic effect of GW501516 observed in the livers CD-HFD-fed mice could occur through an action on HSCs since primary HSCs isolated from Ppard-/- mice showed increased mRNA levels of the profibrotic gene Col1a1. Moreover, PPARβ/δ activation abrogated TGF-β1-mediated cell migration (an indicator of cell activation) in LX-2 cells (immortalized activated human HSCs). Likewise, GW501516 attenuated the phosphorylation of the main downstream intracellular protein target of TGF-β1, suppressor of mothers against decapentaplegic (SMAD)3, as well as the levels of the SMAD3 co-activator p300 via the activation of AMP-activated protein kinase (AMPK) and the subsequent inhibition of extracellular signal-regulated kinase-1/2 (ERK1/2) in LX-2 cells. Overall, these findings uncover a new mechanism by which the activation of AMPK by a PPARβ/δ agonist reduces TGF-β1-mediated activation of HSCs and fibrosis via the reduction of both SMAD3 phosphorylation and p300 levels., This study was partly supported by the grants PID2021-122116OB-I00 (X.P. and M.V-C.) and PID2021-122766OB-I00 (A.M.V.) funded by MICIU/AEI/10.13039/501100011033 and by “ERDF, A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. We also acknowledge support from the CERCA Programme/Generalitat de Catalunya. E.B is a Serra Hunter fellow. Meijian Zhang was supported by a grant from the China Scholarship Council (CSC) (202007565030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effect of lipotoxic hepatocyte-derived extracellular vesicles in pancreas inflammation: essential role of macrophage TLR4 in beta cell functionality

  • Alén, Rosa
  • García-Martínez, Irma
  • Cobo-Vuilleumier, Nadia
  • Fernández-Millán, Elisa
  • Gallardo-Villanueva, Paula
  • Ferreira, Vítor
  • Izquierdo, Manuel
  • Moro, María Ángeles
  • Lizasoain, Ignacio
  • Nieto, Natalia
  • Gauthier, Benoit R.
  • Valverde, Ángela M.
[Aims/hypothesis]: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common feature of obesity and type 2 diabetes. Under lipotoxic stress, hepatocytes release small extracellular vesicles (sEVs) which act locally and contribute to MASLD progression, but their role in beta cell function and development of type 2 diabetes remains largely unexplored. We aimed to examine whether hepatocyte-derived sEVs (Hep-sEVs) under lipotoxic conditions impact on liver and pancreas inflammation and subsequent effects on beta cell function., [Methods]: Primary mouse hepatocytes and Huh7 human hepatocytes were treated with palmitic acid and Hep-sEVs were purified from the culture medium by differential ultracentrifugation. In vitro and in vivo approaches were used to decipher the role of Hep-sEVs in liver and pancreas inflammation and beta cell dysfunction in mouse and human pancreatic islets. The contribution of the Toll-like receptor 4 (TLR4) to Hep-sEV-mediated effects was investigated in pancreatic islets from myeloid-specific TLR4-deficient mice., [Results]: Lipotoxic Hep-sEVs targeted pancreatic islet macrophages and induced TLR4-mediated inflammation. The subsequent inflammatory response downregulated beta cell identity genes and impaired glucose-stimulated insulin secretion in both INS-1 beta cells (p<0.05) and isolated pancreatic islets from mice (p<0.01) and humans (p<0.05). Specific deletion of TLR4 in macrophages protected pancreatic islets against inflammation and the impairment of glucose-stimulated insulin secretion induced by lipotoxic Hep-sEVs. Chronic administration of lipotoxic Hep-sEVs in lean mice induced liver and pancreas inflammation through the recruitment of immune cells. This intervention induced hepatocyte injury and fibrotic damage together with detrimental immunometabolic systemic effects. Insulin resistance in hepatocytes (p<0.01) and a compensatory insulin secretion (p<0.001) that prevented glucose intolerance were also observed in mice treated with lipotoxic Hep-sEVs., [Conclusions/interpretation]: This study has provided evidence of liver and pancreas inflammation and beta cell dysfunction induced by lipotoxic Hep-sEVs. Our data also envision TLR4-mediated signalling in islet macrophages as a key mediator of the effects of lipotoxic Hep-sEVs on beta cell function., This work was supported by grants PID2021-122766OB-I00 (AMV), PID2022-140616OB-I00 (MAM), PID2020-116134RB-I00 (EF-M), PID2021-123083NB-I00 (BRG) and RD21/0006/0001 (ISCIII) (IL) funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by “ERDF/EU”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”, grant EFSD/Boehringer Ingelheim European Research Programme on 'Multi-System Challenges in Diabetes' from the European Foundation for the Study of Diabetes (AMV), P2022/BMD-7227 (Comunidad de Madrid, Spain) (AMV), Fundación Ramón Areces (Spain) (AMV), Horizon-EIC-Pathfinder-Challenge-2023, grant agreement number 101162517, European Union (AMV), Breakthrough T1D (formerly known as JDRF; 3-SRA-2023-1307-S-B to BRG), CIBERdem (ISCIII, Spain) (AMV and BRG), 1R01DK134461 from the National Institute of Diabetes and Digestive and Kidney Diseases (NN) and 1I01BX005093 from the Department of Veterans Affairs (Biomedical Laboratory Research and Development). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government (NN). AMV belongs to the Spanish National Research Council (CSIC)’s Cancer and Metabolism (COMETA) Hubs and Instituto de Investigación Sanitaria La Paz (IdiPaz) (Madrid, Spain). We also acknowledge the Spanish Ministry of Economy and Competitiveness (MINECO) for the postdoctoral contract IJCI-2015-24758 to IG-M and the Spanish Ministry of Education, Culture and Sport (MECD) for the FPU17/02786 grant to RA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mouse and human striatal projection neurons compared - somatodendritic arbor, spines and in silico analyses

  • Kozlov, Alexander K.
  • Blázquez-Llorca, Lidia
  • Benavides-Piccione, Ruth
  • Kastanauskaite, Asta
  • Rojo, Ana I.
  • Muñoz, Alberto
  • Cuadrado, Antonio
  • DeFelipe, Javier
  • Grillner, Sten
Dysfunction of the basal ganglia is implicated in a wide range of neurological and psychiatric disorders. Our understanding of the operation of the basal ganglia is largely derived on data from studies conducted on mice, which are frequently used as model organisms for various clinical conditions. The striatum, the largest compartment of the basal ganglia, consists of 90-95% striatal projection neurons (SPNs). It is therefore crucial to establish if human and mouse SPNs have distinct or similar properties, as this has implications for the relevance of mouse models for understanding the human striatum. To address this, we compared the general organization of the somato-dendritic tree of SPNs, the dimensions of the dendrites, the density and size of spines (spine surface area), and ion channel subtypes in human and mouse SPNs. Our findings reveal that human SPNs are significantly larger, but otherwise the organisation of the dendritic tree (dendrogram) with an average of approximately 5 primary dendrites, is similar in both species. Additionally in both humans and mice, over 90% of the spines are located on the terminal branches of each dendrite. Human spines are somewhat larger (4.3 versus 3.1 μm2) and the terminal dendrites have a uniform diameter in both humans and mice, although somewhat broader in the latter (1.0 versus 0.6 μm). The composition of ion channels is also largely conserved. These data have been used to simulate human SPNs building on our previous detailed simulation of mouse SPNs. We conclude that the human SPNs essentially appear as enlarged versions of the mouse SPNs. This similarity suggests that both species process information in a comparable manner, supporting the relevance of mouse models for studying the human striatum., This study was supported by the Spanish Ministry of Science and Innovation (PID2021-127924NB-I00 funded by MCIN/AEI/10.13039/501100011033) to RBP and JDF, by CIBERNED, ISCIII, CB06/05/0066 to JDF, by the Swedish Research Council (VR-M-2021-01995, VR-M-2024-01995, VR-M-2020-01652), EU/Horizon 2020 no. 945539 (HBP SGA3) and no. 101147319 (EBRAINS 2.0 Project) to SG and AK, the European Union’s Research and Innovation Program Horizon Europe under grant agreement no. 101137289 (the Virtual Brain Twin Project), the Swedish e-Science Research Centre (SeRC), Science for Life Laboratory and KTH Digital Futures to AK, by the Spanish Ministry of Science, Innovation and Universities (PID-2021-122766OB-100, PDC2021-121421-I00, PDC2022-133765-I00), CIBERNED/ISCIII (CB06/05/0010), and The Autonomous Community of Madrid (P2022/BMD-7230) to AIR and AC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

JNK1 in SF1 neurons regulates the central action of thyroid hormones on hepatic lipid metabolism

  • Fernández-González, Iara
  • Freire-Agulleiro, Oscar
  • Ferreira, Vitor
  • Silveira-Loureiro, María
  • Rial-Pensado, Eva
  • Garrido-Gil, Pablo
  • Martínez, Gloria
  • Rada, Patricia
  • Labandeira-Garcia, Jose Luis
  • Mittag, Jens
  • González-García, Ismael
  • Diéguez, Carlos
  • Nogueiras, Rubén
  • Valverde, Ángela M.
  • Davis, Roger J.
  • Sabio, Guadalupe
  • Barca-Mayo, Olga
  • López, Miguel
[Objective] Hypothalamic energy sensors, such as AMP-activated protein kinase (AMPK), and stress sensors, such as c-Jun N-terminal kinase 1 (JNK1, also known as MAPK8) modulate whole body energy balance. While the role of AMPK in steroidogenic factor 1 (SF1) neurons of the VMH has been investigated, the relevance of JNK1 in this neuronal population has not been addressed. Here, we investigated the involvement of JNK1 SF1 on energy homeostasis., [Methods] We generated mice bearing conditional JNK1 disruption through Mapk8 gene deletion in SF1 neurons (Sf1Cre/Jnk1fl/fl). Complete metabolic phenotyping, fasting/refeeding and cold challenges, as well as the central response to triiodothyronine (T3) on brown adipose tissue (BAT) thermogenesis and hepatic lipid metabolism were carried out., [Results] Sf1Cre/Jnk1fl/fl mice displayed decreased body weight, improved glucose tolerance, and reduced hepatic lipid levels. However, Sf1Cre/Jnk1fl/fl did not properly defend their temperature upon cold exposure. While central administration of T3 elicited feeding independent weight loss in both wildtype (Jnk1fl/fl) and SF1Cre/Jnk1fl/fl mice, it did not promote hepatic lipid accretion in null animals., [Conclusions] Our data demonstrated for the first time that JNK1 in SF1 neurons is necessary for the regulation of hepatic lipid metabolism, cold adaptation and central T3 actions., The research leading to these results has received funding from the Xunta de Galicia (IG-G: ED431F 2024/14; IG-G and RN ED431C 2024/10; RN: 2016-PG057; OB-M: ED431F 2020/009 and ED431C 2023/28); Ministerio de Ciencia e Innovación co-funded by the FEDER Program of EU (IG-G: PID2022-141115NA-I00; CD: PID2020-116628 GB-I00; RN: RTI2018-099413-B-I00 and RED2018-102379-T; AM-V; PID2021-122766OB-100; GS: PID2019-104399RB-I00; PMP21/00057; PDC2021-121147-I00 IMPACT-202; OB-M: PID2019-109556RB-I00; PID2022-138436OB-I00; ML: PID2021-128145NB-I00 and PDC2022-133958-I00); European Research Council (RN: ERC Synergy Grant-2019-WATCH- 810331); “la Caixa” Foundation (ID 100010434), (ML: LCF/PR/HR19/52160022 and LCF/PR/HR20/52400013); Fundación AECC (GS: PROYE19047SABI; ML: PRYGN234908LOPE). IG-G and OB-M are supported by Ramón y Cajal Awards (IG-G: RYC2021-031225-I; OB-M: RYC2018-026293-I) from the Ministerio de Ciencia e Innovación of Spain. OF-A was supported by a fellowship from Xunta de Galicia (ED481A-2019/026). CiMUS was supported by the Xunta de Galicia (2020–2023, ED431G/05). CIBER de Fisiopatología de la Obesidad y Nutrición, CIBER de Diabetes y Enfermedades Metabólicas Asociadas and CIBER de Enfermedades Neurodegenerativas are initiatives of ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NRF2 activation by 6-MSITC increases the generation of neuroprotective, soluble α amyloid precursor protein by inducing the metalloprotease gene ADAM17

  • Carnicero-Senabre, Daniel
  • Jiménez-Villegas, José
  • Álvarez-Garrote, Sofía
  • Escoll, Maribel
  • Cuadrado, Antonio
  • Rojo, Ana I.
Better knowledge of the molecular actors governing sequential amyloid precursor protein (APP) proteolysis is crucial to endorse novel therapies aimed to delay Alzheimer's disease (AD) progression. ADAM17 (A Disintegrin and Metalloproteinase 17) is a type-I transmembrane protease involved in the non-amyloidogenic processing of APP that contributes to the maintenance of synaptic functions. In this work, we analyzed the 5′-flanking region and first intron of ADAM17 gene employing an in silico analysis. This strategy evidenced two regions which concentrate the binding sites of diverse transcription factor-families, including members of the b-ZIP small MAF, NRF2 and BACH1 proteins. Then, we found that the natural isothiocyanate 6-MSITC (6 methylsulfinyl hexyl isothiocyanate) increased both mRNA and protein levels of ADAM17 in an NRF2-dependent manner. In line, SH-SY5Y neurons released higher levels of the soluble APPα peptide as a result of ADAM17 activation. Overall, our study identifies inducible expression of ADAM17, and consequently protease activity, by NRF2., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID-2021-122766OB-100 and PDC2021-121421-I00, PDC2022-133765-I00), CIBER -Consorcio Centro de Investigación Biomédica en Red-CB06/05/0010, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and The Autonomous Community of Madrid (grant P2022/BMD-7230). DCS is a holder of an FPI contract of MICINN (Ministry of Science and Innovation, FPI-2020, PRE2020-091886). JJV is holder of a FPU contract of MIU (Ministry of Universities, FPU2020, FPU20/03326). This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology) (www.cost.eu) (https://benbedphar.org/about-benbedphar/)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NRF2 deficiency is associated with synaptic alterations and ether-linked phospholipid imbalance in the hippocampus

  • Carnicero-Senabre, Daniel
  • Barata, Mariana A.
  • Jiménez-Villegas, José
  • Guimas Almeida, Claudia
  • Cuadrado, Antonio
  • Rojo, Ana I.
Synaptic loss is a key factor in the cognitive decline observed during aging and in neurodegenerative diseases such as dementia, where synaptopathy plays a central role in hippocampal dysfunction. In this study, we investigated the role of NRF2, a master regulator of cellular homeostasis, in maintaining synaptic integrity. We assessed synaptic contacts both in vitro and in vivo and found that NRF2 deficiency leads to a significant reduction in vGLUT1 levels, accompanied by a decrease in the number of synaptic contacts. Because synapses are subject to highly dynamic membrane remodeling processes, we analyzed the lipid composition of hippocampi and synaptosomes from NRF2-deficient and wild-type mouse littermates. Our results revealed an accumulation of ether-linked phospholipids in NRF2-deficient mice. When primary neuronal and organotypic cultures were exposed to an ether-lipid precursor, synaptic density decreased. By contrast, the NRF2 activator 6-(methylsulfinyl)hexyl isothiocyanate (6-MSITC or hexaraphane) prevented synaptic loss. Although ether lipids are abundant components of neuronal membranes, their specific role in synaptic function and in age-related loss of homeostatic balance remains poorly understood. This study is the first to demonstrate that NRF2 plays an essential role in preserving synaptic homeostasis through lipid metabolism, suggesting its relevance in the context of aging and neurodegenerative diseases., This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (grants PID2019-110061RB-I00, PID-2021-122766OB-100 and PDC2022-133765-I00), Ramón Areces Foundation (2024_Rojo), CIBER -Consorcio Centro de Investigación Biomédica en Red-CB06/05/0010, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and The Autonomous Community of Madrid (grant P2022/BMD-7230). DCS holds an FPI contract of MICINN (Ministry of Science and Innovation, FPI-2020, PRE2020-091886). JJV holds an FPU PhD fellowship from the Spanish MIU (Ministry of Universities, FPU2020, FPU20/03326). This project has received funding (to CGA) from the Research Unit UID/04462: iNOVA4Health - Programa de Medicina Translacional and by the Associated Laboratory LS4FUTURE (LA/P/0087/2020), all financially supported by Fundação para a Ciência e Tecnologia (FCT)/Ministério da Educação, Ciência e Tecnologia and co‐funded by FEDER under the PT2020 Partnership Agreement); CGA holds CEEC/iNOVA4Health contract (FCT); and MB holds an FCT doctoral fellowship (10.54499/2020.06758. BD). This article is based upon work from COST Action CA20121, supported by COST (European Cooperation in Science and Technology) (www.cost.eu) (https://benbedphar.org/about-benbedphar/)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Platelet C3G protects from liver fibrosis, while enhancing tumor growth through regulation of the immune response

  • Baquero, Cristina
  • Iniesta-González, Minerva
  • Palao, Nerea
  • Fernández-Infante, Cristina
  • Cueto-Remacha, Mateo
  • Mancebo, Jaime
  • Cámara-Fuentes, Samuel de la
  • Rodrigo-Faus, María
  • Valdecantos, M. P.
  • Valverde, Ángela M.
  • Sequera, Celia
  • Manzano, Sara
  • Cuesta, Ángel M.
  • Gutiérrez-Uzquiza, Álvaro
  • Bragado, Paloma
  • Guerrero, Carmen
  • Porras, Almudena
Primary liver cancer usually occurs in the context of chronic liver disease (CLD), in association with fibrosis. Platelets have emerged as important regulators of CLD and liver cancer, although their precise function and mechanism of action need to be clarified. C3G (RapGEF1) regulates platelet activation, adhesion, and secretion. Here we evaluate the role of platelet C3G in chemically induced fibrosis and liver cancer associated with fibrosis using genetically modified mouse models. We found that while overexpression of full-length C3G in platelets decreased liver fibrosis induced by chronic treatment with CCl4, overexpressed C3G lacking the catalytic domain did not, although in both cases platelet recruitment to the liver was similar. In addition, C3G deletion in platelets (PF4-C3GKO mouse model) increased CCl4-induced liver damage and hepatic fibrosis, reducing liver platelets and macrophages. Moreover, early liver immune response to CCl4 was altered in PF4-C3GKO mice, with a remarkable lower activation of macrophages and increased monocyte-derived macrophages compared to WT mice. On the other hand, in response to DEN+CCl4, PF4-C3G WT mice exhibited more and larger liver tumors than PF4-C3GKO mice, accompanied by the presence of more platelets, despite having less fibrosis in previous steps. Liver immune cell populations were also differentially regulated in PF4-C3GKO mice, highlighting the higher number of macrophages, likely with a pro-inflammatory phenotype, present in the liver in response to chronic DEN+CCl4 treatment. Proteins upregulated or downregulated in platelet-rich plasma from PF4-C3GKO compared to WT mice might regulate the immune response and tumor development. In this regard, enrichment analyses using proteomic data showed changes in several proteins involved in platelet activation and immune response pathways. Additionally, the higher secretion of CD40L by PF4-C3GKO platelets could contribute to their antitumor effect. Therefore, platelet C3G presents antifibrotic and protumor effects in the liver, likely mediated by changes in the immune response. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness and Science, Innovation and Universities (PID2022-137717OB-C21 to AP/AMC; PID2019-104143RB-C22 to AP; PID2022-137717OB-C22 to CG; PID2019-104143RB-C21 to CG; PID2019-104991RB-I00 and PID2022-136959OB-I00 to PB, PID2020-117650RA-I00 and CNS2023-144109 to AG-U, PID-2021-122766OB-100 to AVM and funded by MICIU/AEI/10.13039/501100011033). All funding was cosponsored by the European ‘ERDF A way of making Europe’. CB was supported by Grant PID2019-104143RB-C22. NP was a recipient of a Formacion de Profesorado Universitario fellowship from the Spanish Ministry of Education. MI is supported by a predoctoral contract from Comunidad de Madrid. MC is a recipient of a predoctoral contract from UCM., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Transcription factor NRF2: New therapeutic approach to modify Parkinson's disease progression

  • Rojo, Ana I.
  • Esteras, Noemí
  • Cuadrado, Antonio
  • Lastres Becker, Isabel
The lack of neuroprotective therapies for Parkinson's disease (PD) is a critical issue with significant societal and scientific relevance. The medications available, such as levodopa and dopamine agonists, focus solely on managing symptoms by temporarily replenishing dopamine or mimicking its effects. While these treatments provide relief, they do not address the root cause of the disease, allowing neurodegeneration to continue unchecked. This is why it is necessary to find new therapeutic targets that slow down the progression of the neurodegenerative process. The search for a single target capable of modulating oxidative stress, neuroinflammation, and the alteration of proteostasis associated with PD has focused on the transcription factor NRF2. Genetic variations in the NRF2 encoding NFE2L2 gene promoter that may influence disease risk and onset age have been associated with disease risk or prevention. This basic leucine-zipper protein orchestrates the expression of a battery of cytoprotective genes, all of which share a specific enhancer known as the antioxidant response element (ARE). These genes are pivotal in a variety of cellular processes, including detoxification reactions across phases I, II, and III, metabolism of glutathione and the peroxiredoxin/thioredoxin system, NADPH generation, neuroinflammation, iron management/ferroptosis, and proteostasis. Given NRF2's ability to modulate several PD's key features, various pharmacological approaches have been explored. This chapter examines the role of NRF2 in PD pathogenesis and discusses promising compounds validated in mouse models that warrant clinical trial, This work was supported by MINECO (Grants PID2022-137065OB-I00 to I.L.-B.; PID-2021-122766OB-100, PDC2021-121421-I00, PDC2022-133765-I00 to AIR and AC; PID2022-137011OA-I00/AEI/10.13039/501100011033/FEDER, EU to NE), ISCiii CIBERNED (CB06/05/0089 to IL-B and NE; CB06/05/0010 to AC and AIR) and the Autonomous Community of Madrid (P2022/BMD-7230) to AIR and AC. NE is funded by a Ramón y Cajal Fellowship (RYC2021-034267-I) from the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033., Peer reviewed